About Viatris
Frequently Asked Questions
Q: What is Viatris?
A: Viatris is a new company that is the combination of Mylan and Upjohn, a legacy division of Pfizer.
A: Viatris is a new company that is the combination of Mylan and Upjohn, a legacy division of Pfizer.
Q: Which products from Upjohn, a legacy division of Pfizer, will be included in the transition to Viatris?
A: The following products will be included in the transition to Viatris:
A: The following products will be included in the transition to Viatris:
- CADUET® (amlodipine besylate/atorvastatin calcium) tablets
- CARDURA® (doxazosin mesylate) tablets
- CARDURA® XL (doxazosin mesylate extended
- CELEBREX® (celecoxib) capsules
- DETROL® (tolterodine tartrate) tablets
- DETROL® LA (tolterodine tartrate) extended-release capsules
- DILANTIN® (extended phenytoin sodium) capsules
- EFFEXOR XR® (venlafaxine HCl) extended-release capsules
- GEODON® (ziprasidone HCl)
- INSPRA® (eplerenone) tablets
- LIPITOR® (atorvastatin calcium) tablets
- LYRICA® (pregabalin) Capsules CV
- LYRICA® CR (pregabalin) extended-release tablets
- NEURONTIN® (gabapentin)
- NITROSTAT® (nitroglycerin) sublingual tablet
- NORVASC® (amlodipine besylate) tablets
- RELPAX® (eletriptan hydrobromide) tablets
- REVATIO® (sildenafil) oral suspension
- REVATIO® (sildenafil) tablets
- SERMION® (nicergoline) tablets
- VIAGRA® (sildenafil citrate) tablets
- XALATAN® (latanoprost ophthalmic solution) 0.005%
- XANAX® CIV (alprazolam) tablets
- ZOLOFT® (sertraline hydrochloride)
Q: How long will Pfizer manage the Patient Assistance Program for legacy Upjohn products?
A: Pfizer will continue to manage the Patient Assistance Program for certain Upjohn products until December 31, 2021.
A: Pfizer will continue to manage the Patient Assistance Program for certain Upjohn products until December 31, 2021.
Q: How will this transition impact patient access to medicines?
A: There will be no impact to patients eligible for, or currently participating in, the Pfizer Patient Assistance Program.
A: There will be no impact to patients eligible for, or currently participating in, the Pfizer Patient Assistance Program.
Q: Will there be any impact to my current enrollment for these medicines?
A: There will be no impact to a patient’s current enrollment in the Pfizer Patient Assistance Program for these medications.
A: There will be no impact to a patient’s current enrollment in the Pfizer Patient Assistance Program for these medications.
Q: I receive other Pfizer medicines, will there be changes there too?
A: There will be no changes to how patients access their other Pfizer medicines.
A: There will be no changes to how patients access their other Pfizer medicines.
Q: Where can I go for more information about Viatris?
A: For more information about Viatris, please visit their website at www.Viatris.com/PAP or call 1-888-417-5782.
A: For more information about Viatris, please visit their website at www.Viatris.com/PAP or call 1-888-417-5782.